Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INBX
INBX logo

INBX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

INBX News

Inhibrx Biosciences Reports Promising Interim Results for Ozekibart in Colorectal Cancer

4h agoNASDAQ.COM

Inhibrx Biosciences' Promising Drug Pipeline Attracts Major Interest

4h agostocktwits

Global Drugmakers Pursue $8B Cancer Drug Deal with Inhibrx

5h agoseekingalpha

EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA

7h agomoomoo

Inhibrx Biosciences to Host Live Webcast for Clinical Update

1d agoPRnewswire

Inhibrx to Host Live Webcast for Clinical Update

1d agoNewsfilter

Inhibrx Biosciences Receives Buy Rating from Stifel

Apr 08 2026seekingalpha

Inhibrx Biosciences Reports 2025 Financial Results

Mar 19 2026PRnewswire

INBX Events

04/22 12:00
U.S. Stocks Rise on Ceasefire Agreement, S&P 500 Up 0.81%
The major averages were broadly higher near noon following the announcement that the U.S. will extend its ceasefire with Iran indefinitely. Traders even appear to be shrugging of comments from President Trump that Iran's government is "seriously fractured," along with news that Vice President JD Vance has paused his trip to Pakistan for peace talks. As equities rise, there are already reports of renewed tensions in the Strait of Hormuz and continued disruptions to shipping, which is keeping oil prices elevated.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Boeingreportedearnings and revenueAT&Treportedand reiterated its FY26 earnings guidanceAlibabaand Tencentare in talks to invest in DeepSeek,Elon Musk's SpaceX said it has thelater this year for $60BPalantirand the USDA signed a $300M2. WALL STREET CALLS:Wells FargoAirbnbto Overweight on "significant business inflection"BofATwilioto Buy from UnderperformBiogento Buy at UBSZscalerto Equal Weight at Morgan StanleyBarclaysPrudentialto a sell-equivalent rating amid "too many headwinds"3. AROUND THE WEB:Callisto Research says it is short Sportradar, "a self-styled 'Sports Integrity' leader with ties to illegal gambling, sanctioned parties, criminals, and a completely fake regulator."Robinhood'sventure fund is investing $75M in OpenAI, signaling a reconciliation after last year's dispute over Robinhood's tokenized "access" to OpenAI shares, which OpenAI publicly disavowed, NY Times saysInhibrx Biosciences'INBRX-106 cancer drug is drawing interest from Merckand Japan's Ono Pharmaceuticals, Reuters reportsAfter Bloomberg reported yesterday, citing sources, that Deutsche Telekomis considering a full combination with T-Mobile, CNBC's David Faber said his sources call such speculation "way ahead of itself" and that there is "nothing imminent at all" regarding any type of such dealMicronis pushing U.S. lawmakers to pass the "MATCH Act," which would tighten export restrictions on chipmaking equipment used by Chinese semiconductor firms and close gaps in existing controls, Reuters says4. MOVERS:GE Vernovaincreases afterand raising its guidance for FY26Kopin (KOPN) higher after being awarded afor optic modulesRogers Communicationsgains in New York afterbacking its guidance for FY26, and declaring a C$0.50 per share quarterly dividendCalix (CALX) lower afterand providing guidance for FY26Sonoco (SON) and TE Connectivityfall in New York after5. EARNINGS/GUIDANCE:NVR (NVR), with EPS and revenue missing consensusStifel, with EPS beating consensusMoodyand reaffirmed its guidance for FY26Masco, with CEO Jon Nudi commenting on "strong first quarter operating results in an extremely dynamic environment"Teledyneand raised its guidance for FY26INDEXES:Near midday, the Dow was up 0.68%, or 333.97, to 49,483.35, the Nasdaq was up 1.27%, or 307.88, to 24,567.84, and the S&P 500 was up 0.81%, or 57.01, to 7,121.02.
04/22 09:40
Inhibrx Trading Halted Due to Volatility
Inhibrx trading halted, volatility trading pause

INBX Monitor News

Inhibrx Biosciences Hosts Webcast for Ozekibart Clinical Update

Apr 22 2026

INBX Earnings Analysis

No Data

No Data

People Also Watch